Title
Clostridium difficile Colitis and Neutropenic Fever Associated with Docetaxel Chemotherapy in a Patient with Advanced Extramammary Paget’s Disease

Author(s)
Nonomura, Yumi; Otsuka, Atsushi; Endo, Yuichiro; Fujisawa, Akihiro; Tanioka, Miki; Kabashima, Kenji; Miyachi, Yoshiki

Citation
Case Reports in Dermatology (2012), 4(2): 177-180

Issue Date
2012-08

URL
http://hdl.handle.net/2433/160228

Right
Copyright 2012 S. Karger AG, Basel. This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License (www.karger.com/OA-license), applicable to the online version of the article only. Distribution for non-commercial purposes only.

Type
Journal Article

Textversion
Publisher
Kyoto University
Clostridium difficile Colitis and Neutropenic Fever Associated with Docetaxel Chemotherapy in a Patient with Advanced Extramammary Paget’s Disease

Yumi Nonomura  Atsushi Otsuka  Yuichiro Endo  Akihiro Fujisawa  
Miki Tanioka  Kenji Kabashima  Yoshiki Miyachi  
Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan

Key Words  
Clostridium difficile colitis  ∙  Neutropenic fever  ∙  Extramammary Paget’s disease  ∙  Docetaxel

Abstract  
Extramammary Paget’s disease is a rare cutaneous malignant neoplasm. Previous studies indicated the efficacy of docetaxel in advanced cases. The common side effects of docetaxel are usually tolerable and seldom life-threatening. We experienced a case of severe pseudomembranous colitis and neutropenic fever that developed just after the first cycle of docetaxel chemotherapy. To the best of our knowledge, there are few reports of pseudomembranous colitis associated with docetaxel administration for skin cancers. The patient showed complete resolution of her symptoms within 2 weeks with an oral metronidazole therapy. During the second and third cycles, the patient received docetaxel safely with lower doses. The present case indicated that pseudomembranous colitis should be included in the differential diagnosis when assessing patients who develop severe diarrhea during systemic chemotherapy with docetaxel.

Introduction  
Extramammary Paget’s disease (EMPD) is a rare cutaneous malignant neoplasm that arises in areas in the apocrine glands. Although EMPD is usually a non-invasive intraepithelial adenocarcinoma, some cases of EMPD infiltrate the dermis and show lymph node or distant metastases. Previous studies have shown cases of advanced EMPD successfully treated with docetaxel [1]. Common side effects of docetaxel are
usually tolerable and seldom life-threatening. We experienced a case of severe *Clostridium difficile* colitis and neutropenic fever that developed just after the first docetaxel chemotherapy for EMPD. To the best of our knowledge, there are few reports of *C. difficile* colitis associated with docetaxel use for skin cancer.

**Case Report**

A 67-year-old Japanese female with stage IV EMPD of the vulva was treated with 75 mg/m² docetaxel for the first time. Two weeks before docetaxel administration, oral cefcapene had been administered for 3 days at another clinic to prevent infection after biopsy of the vulva. On day 4 of the first cycle therapy, she developed severe watery diarrhea that quickly became bloody. On day 6, she was immediately admitted to the hospital. Physical and other examinations revealed grade 3 neutropenic fever and diarrhea (Common Terminology Criteria for Adverse Events version 4.0) more than 10 times per day, with slight abdominal pain but no nausea or vomiting. She was treated with an injection of granulocyte colony-stimulating factor and piperacillin/tazobactam. Stool enzyme immunoassays for *C. difficile* toxins were positive. *C. difficile* colitis was diagnosed, and therefore an additional antibiotic therapy with oral metronidazole and antibiotic-resistant lactic acid bacteria drug was initiated. The patient had complete resolution of her symptoms within 2 weeks. One month after the administration of docetaxel, we found that the tumor had remarkably decreased in size and the serum tumor marker test showed a considerably decreased level of carcinoembryonic antigen (from 158 ng/ml before to 13 ng/ml after chemotherapy). Therefore, we decided to pursue docetaxel treatment with a decreased dose of 37.5 mg/m² after informed consent was obtained. During the second and third cycle, no apparent side effects other than neutropenia without fever were observed. The tumor continued to decrease in size, and the serum carcinoembryonic antigen level was 5 ng/ml after the third cycle of chemotherapy.

**Discussion**

*C. difficile* colitis is a well-known complication of antibiotic treatment that can also be observed, albeit rarely, with certain chemotherapeutic agents [2]. Some chemotherapeutic agents are also associated with different grades of inflammation and necrosis of the colonic mucosa with alteration of the intestinal flora [2]. This has been proposed as the pathophysiological mechanism responsible for the development of *C. difficile* colitis in some patients receiving these drugs [2]. Methotrexate has been the most commonly implicated agent of this class but platinum-containing drugs and taxanes are well-known for their potential to cause extensive inflammatory changes in the colonic mucosa, therefore creating a favorable environment for the overgrowth of *C. difficile* and production of its exotoxins [2]. Including the present case, there are 5 cases of *C. difficile* colitis or pseudomembranous colitis related to docetaxel use (table 1) [2, 3]. The patients developed colitis within 4 to 10 days after docetaxel administration, and 3 of the 5 patients developed neutropenia at the same time. The immunosuppressive condition due to neutropenia and inflammatory changes in the colonic mucosa caused by docetaxel might contribute to the development of severe *C. difficile* colitis. The cases indicated that *C. difficile* colitis should be included in the differential diagnosis when assessing patients who develop severe diarrhea during systemic chemotherapy with docetaxel. Including the present case, only 2 cases had positive stool assays for *C. difficile* toxin. Negative stool assays for *C. difficile* toxins should not lead the clinician away from this diagnosis if there is a strong suspicion of this disease. Colonoscopy or sigmoidoscopy are useful diagnostic procedures as the presence of pseudomembranes in the colon is pathognomonic of *C. difficile*-associated
disease. The present case also indicated the possibility that docetaxel treatment can be continued with lower doses even after the patient developed \textit{C. difficile} colitis associated with docetaxel chemotherapy.

**Disclosure Statement**

None of the authors have a conflict of interest to declare.

**Table 1.** Review of the 5 cases of \textit{C. difficile} colitis or pseudomembranous colitis associated with docetaxel use

<table>
<thead>
<tr>
<th>Case 1</th>
<th>Case 2</th>
<th>Case 3</th>
<th>Case 4</th>
<th>Case 5 (present case)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age/sex, years</strong></td>
<td>83/male</td>
<td>47/male</td>
<td>41/female</td>
<td>45/female</td>
</tr>
<tr>
<td><strong>Diagnosis</strong></td>
<td>adenocarcinoma of the pancreas</td>
<td>adenocarcinoma of the lung</td>
<td>invasive ductal carcinoma of the breast</td>
<td>breast cancer</td>
</tr>
<tr>
<td><strong>Chemotherapy (21-day cycles for all)</strong></td>
<td>day 1 and 8: docetaxel 30 mg/m$^2$; days 1–14: capecitabine 1,600 mg/m$^2$</td>
<td>day 1: docetaxel 70 mg/m$^2$ and carboplatin AUC 6</td>
<td>day 1: docetaxel 70 mg/m$^2$ and cisplatin 70 mg/m$^2$</td>
<td>day 1: docetaxel 75 mg/m$^2$ and doxorubicin 50 mg/m$^2$</td>
</tr>
<tr>
<td><strong>Clinical presentation</strong></td>
<td>severe bloody diarrhea and dehydration on cycle 1 day 8</td>
<td>severe bloody diarrhea, febrile neutropenia and diffuse abdominal pain on cycle 3 day 10</td>
<td>severe diarrhea positive for occult blood, abdominal pain and leukocytosis on cycle 2 day 9</td>
<td>severe watery diarrhea, vomiting, abdominal pain and neutropenic fever on cycle 1 day 6 and cycle 2 day 4</td>
</tr>
<tr>
<td><strong>Antibiotic exposure</strong></td>
<td>no</td>
<td>no</td>
<td>unknown</td>
<td>ceftazidime 1 week before</td>
</tr>
<tr>
<td><strong>C. difficile toxin</strong></td>
<td>negative (3 samples)</td>
<td>positive (2 of 3 samples)</td>
<td>negative (3 samples)</td>
<td>negative</td>
</tr>
<tr>
<td><strong>Endoscopic findings</strong></td>
<td>pseudomembranes in the rectum, sigmoid and descending colon</td>
<td>pseudomembranes in the sigmoid and descending colon</td>
<td>moderate to severe mucosal inflammation of the sigmoid and the rectum with diffuse subepithelial hemorrhages</td>
<td>moderate inflamed rectal mucosa covered with pseudomembranes</td>
</tr>
<tr>
<td><strong>Treatment</strong></td>
<td>oral vancomycin</td>
<td>IV metronidazole and oral vancomycin</td>
<td>oral metronidazole</td>
<td>metronidazole and oral vancomycin</td>
</tr>
<tr>
<td><strong>Outcome</strong></td>
<td>symptoms resolved</td>
<td>symptoms resolved</td>
<td>symptoms resolved</td>
<td>symptoms resolved</td>
</tr>
</tbody>
</table>
References

